Looking for a Blood Epigenetic Signature to Predict Female Infertility

Launched by UNIVERSITÀ VITA-SALUTE SAN RAFFAELE · Oct 18, 2023

Keywords

ClinConnect Summary

This clinical trial is looking into the reasons behind female infertility, specifically how the quality of eggs (oocytes) decreases over time. Researchers are trying to develop a way to predict infertility by examining changes in DNA found in the blood. This method is non-invasive, meaning it doesn't require any surgical procedures, making it easier for women to participate. The goal is to create a reliable blood test that can help identify women who might face challenges with fertility.

To be eligible for this study, women must be between the ages of 18 and 43 and currently experiencing infertility issues or repeated pregnancy losses. Unfortunately, those under 18 or over 44, as well as women who have had certain types of ovarian surgeries or whose partners have severe infertility issues, cannot join the trial. Participants can expect to contribute to important research that may lead to better understanding and treatment options for infertility in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 18\< age \<43, Infertile woman undergoing ART, recurrent pregnancy loss
• Exclusion Criteria:
• • age \< 18 or \> 44, previous ovarian surgery, severe male factor infertility